Brain-computer interfaces have largely been associated with Elon Musk‘s Neuralink and its implantable chips. But Apple Inc‘s (NASDAQ:AAPL) quiet acquisition of startup Sonera suggests the iPhone maker is pursuing a similar long-term ambition through a very different route: bringing brain and muscle sensing to consumer wearables rather than the operating room.
Apple’s Brain Tech Bet
Apple acquired California-based startup Sonera in May, according to newly disclosed European Union filings. The startup developed compact magnetic sensors capable of detecting tiny magnetic fields generated by the brain and muscles without requiring skin contact or implanted devices.
Founded by UC Berkeley researchers Nishita Deka and Dominic Labanowski, Sonera initially focused on muscle monitoring before expanding into technology that could eventually enable everyday brain sensing. The company’s website has since gone offline following the acquisition.
Apple has not publicly disclosed how it plans to use the technology, but the acquisition aligns with the company’s broader push into digital health, accessibility and more natural ways for users to interact with its devices.
Neuralink’s Different Path
The comparison with Neuralink is inevitable, but the two companies appear to be solving different parts of the same problem.
Neuralink is developing implantable brain-computer interfaces designed to capture high-fidelity neural signals, with an initial focus on helping people with severe neurological conditions regain communication and physical control.
Apple’s approach, by contrast, appears to prioritize accessibility and scale. If non-invasive sensors become sufficiently accurate, they could eventually be integrated into products such as the Apple Watch, Vision Pro or other wearable devices, enabling new forms of gesture recognition, health monitoring or hands-free interaction without surgery.
That distinction reflects a broader trade-off in brain-computer interfaces: implanted devices can capture richer neural data, while wearable sensors have the potential to reach hundreds of millions of consumers if the technology matures.
What Investors Should Watch
Apple’s acquisition of Sonera does not mean brain-controlled consumer devices are around the corner. Non-invasive sensing remains an emerging technology, and the company has yet to reveal any commercial roadmap.
The bigger takeaway is strategic. Apple has consistently expanded its ecosystem by bringing advanced health technologies—from heart rhythm monitoring to hearing health—into everyday consumer devices.
If brain and muscle sensing follows a similar path, the acquisition could represent an early investment in what may become the next generation of human-device interaction, even if Apple’s route looks very different from Musk’s Neuralink.
Photo by Andrey Bayda via Shutterstock
Login to comment